CKClaas Kirchhelle

Claas Kirchhelle

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claas Kirchhelle has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial Resistance: Just Transitions for Shared Futures – CORRIGENDUM

    by Sheila Varadan, Sara de Wit, Miriam Waltz, Claas Kirchhelle

  • Antimicrobial Resistance: Just Transitions for Shared Futures

    by Claas Kirchhelle, Sara de de Wit, Miriam Waltz, Sheila Varadan, Tess Johnson, Romina Rekers, Calvin Ho, Marina Joubert, Gloria Rukomeza, Vijayashree Yellappa, et al.

    This seminar explores the special journal issue ‘Just Transitions’ as a framework to examine the social, ethical, and ecological dimensions of antimicrobial resistance (AMR). It reflects on how AMR intersects with injustice, marginality, and inequality, and considers how principles of solidarity, inclusivity, and sustainability can guide equitable and shared futures with the microbial world. Introduction to Special Issue - Antimicrobial Resistance: Just Transition for Shared Futures Talk by Claas Kirchhelle, Sara de Wit, Miriam Waltz, Sheila Varadan Roundtable I: Theorising justice in a ‘just’ transition Talk by Tess Johnson, Romina Rekers, Calvin Ho, Sheila Varadan Roundtable II: Equity and inclusivity in AMR transitions Talk by Marina Joubert, Gloria Rukomeza, Vijayashree Yellappa, Deepshikha Batheja Roundtable III: AMR Governance and policy in transition Talk by Nicolas Fortane, Ashish Giri, Nadya Wells, Sonia Lewycka, Edna Mutua Conclusion / Wrap up Talk by Jeffrey R. Wilson


  • Introduction to Special Issue - Antimicrobial Resistance: Just Transition for Shared Futures

    by Claas Kirchhelle, Sara de de Wit, Miriam Waltz, Sheila Varadan

    Antimicrobial resistance (AMR) is among the most urgent and complex global health challenges of our time. But it is also a human rights and social justice crisis, deeply entwined with planetary environmental crises. A new Special Issue in Public Humanities, Antimicrobial Resistance: Just Transitions for Shared Futures brings together scholars from the humanities, social sciences and global health to re‑imagine how we live with AMR and our microbial world. Guest edited by Dr Sheila Varadan, Dr Sara de Wit, Dr Miriam Waltz and Dr Claas Kirchhelle, the issue applies “just transitions” – a concept rooted in climate justice – to draw out the societal, ethical and ecological dimensions of AMR. The editors argue that while current AMR governance has historically focused on research and innovation, drug stewardship and individual behavioral approaches, it has failed to address the deeper inequities and environmental pressures driving resistance. For communities already living with polluted water, working in unsafe conditions or coping with little or no access to health care, drug‑resistant infections are not a future threat – they are an everyday reality. With humanities and social science scholars from over 20 countries, this issue interrogates AMR through a global lens using four interlinked themes: justice, equity, inclusivity and governance. Authors explore how justice must extend to marginalized communities and even non‑human life; how structural inequalities shape vulnerability and access to treatment; how inclusive, participatory governance can improve public engagement; and how global policy must move beyond short‑term stewardship to the sustainable and equitable management of microbial environments. This special use calls for a widening in the AMR discourse from a public health crisis to a human rights and environmental justice issue — intimately connected to climate change, biodiversity loss and pollution. It calls for a shift in the narrative from a “war against microbes” to a long‑term process of negotiation and co‑existence: recognizing that microbes are essential to sustaining all life on Earth. By applying a “just transitions” lens, the editors argue for an open‑ended, equitable approach to managing AMR that values diverse knowledge systems, and prioritizes sustainability and solidarity.

  • Open Access

    Antimicrobial Resistance and the Right to a Healthy Environment: Crown Jewel or Damp Squib?

    by Wendy Boucrot, Sheila Varadan, Claas Kirchhelle

    Antimicrobial resistance (AMR) is among the most urgent global health challenges of our time. However, it is also a human rights and environmental crisis deeply entwined with climate change, biodiversity loss, and pollution. Historically, AMR was framed as a public health challenge, with little consideration given to its environmental factors and human rights implications. In this article, we examine AMR through the lens of the right to a healthy environment, exploring whether a normative human rights framework could open up new avenues to seek justice and accountability for the environmental drivers of AMR. Drawing on recent developments in international law, we suggest that this newly recognized right widens the narrative of AMR, drawing attention to the role of microbial environments in the global ecosystem and compelling more holistic responses that extend beyond public health interventions to address the underlying structural inequalities and environmental drivers of AMR.


  • Assetizing Diversity: Microbial Culture Collections in an Age of Biotechnology, Biodiversity, and Speculative Value Generation (1972–2022)

    by Claas Kirchhelle, Frédéric Vagneron

    This article traces the history of microbial culture collections to explore the evolution of microbial biodiversity conservation and biotechnological valorization between 1972 and 2022. It shows how a progressive assetization of microbial value led to an enclosure of the global microbial commons. Culture collections were enablers and victims of this change. Analyzing collections across Europe, the Americas, and Asia as well as the World Federation of Culture Collections (WFCC), the article reconstructs how culture collections functioned as a key infrastructure for the globalized take-off of the biotechnology industry. Biotechnological investment in microbial exploitation created important revenue streams amidst public funding cuts and collections' declining role as research hubs. However, pressure to control and generate income from microbial assets also shifted moral economies governing microbial exchange and led to commercial rivalry between collections. While biodiversity concerns prompted a reconceptualization of collections as microbial arks, the 1993 Convention on Biological Diversity's recognition of national sovereignty over bioresources further complicated microbial conservation. Actors such as the WFCC and Organisation for Economic Co-operation and Development (OECD) tried to reconcile access and benefit sharing (ABS) obligations and intellectual property (IP) via guidelines, networking, and accreditation. However, entrenched asymmetries in the global distribution of ex situ conservation infrastructures and microbial value generation remained unaddressed despite passage of the 2010 Nagoya protocol on ABS. Meanwhile, advances in sequencing and synthetic biology not only highlighted biases in existing collections, but also pointed to an era in which in silico approaches to biodiversity might supersede existing in vitro museums.

  • Open Access

    (Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

    by Claas Kirchhelle, Mirza Y Alas Portillo, Mark D M Davis, Assa Doron, Anahí Dreser, Nicolas Fortané, Christian Haddad, Stephen Hinchliffe, Samuel Kariuki, Sonia Lewycka, et al.


  • Open Access

    Antimicrobial Resistance: Just Transitions for Shared Futures

    by Sheila Varadan, Sara de Wit, Miriam Waltz, Claas Kirchhelle

    In the last decade, we have seen escalating warnings of a looming "antibiotic apocalypse"-a future where antimicrobial resistance (AMR) overtakes modern medicine and routine procedures such as minor surgery or uncomplicated childbirth become costly and lifethreatening. 1 For much of the world, this is already happening. In many lower-and middleincome countries, the threat of drug-resistant infections is an everyday reality-antimicrobial drugs have long since lost their effectiveness or were never accessible in the first place. 2 While this health crisis is being linked to AMR, it reflects deeper structural inequalities and unseen injustice. 3 Narratives of AMR as a "silent pandemic" or looming global health threat obscure these realities and fail to recognise that drug-resistance is already exacting a profound and uneven toll on human health and development, particularly among vulnerable and marginalised communities. 4 In truth, our interdependence with the microbial world is far more complex, and the implications of AMR extend well beyond the clinical setting and economic burden of drug resistance in humans. 5 Microbes are the basis of all life on Earth. Microbes are key to sustaining the biosphere, regulating planetary biogeochemical cycling, and constitute 70%-90% of all cells within the human body. 6 Maintaining healthy, sustainable, and diverse microbial environments is essential for all life. 7 AMR is itself a naturally occurring process within microbial ecosystems: microbes produce antimicrobial substances to compete or communicate with each other and have evolved complex resistance mechanisms to survive exposure to organic and inorganic antimicrobial substances. 8 Greater exposure to antimicrobials increases selection for resistant organisms


  • A research agenda advancing climate change and antimicrobial resistance as interconnected issues

    by Kelly Moon, Bianca van Bavel, Lea Berrang Ford, Kerry Badger, Laura Carter, Barbara Evans, William H. Gaze, Philip Howard, Arshnee Moodley, Kasim Allel, et al.